Acular (ketorolac tromethamine ophthalmic solution) 0.5%

Company
Allergan

Approval Status
Approved November 1997

Treatment for
post-surgical inflammation following cataract extraction

Possible similar drugs
Acular

Areas
Eye Health / Ophthalmology

Acular has now been approved by the FDA for post-surgical inflammation following cataract extraction. Acular is administered between one and four times daily starting 24 hours after surgery for two weeks. It can be used with antibiotics, beta blockers, carbonic anhydrase inhibitors, cycloplegics, and mydriatics. For itch, Acular is administered between one and four times daily as needed.

Adverse events include transient stinging and burning upon application.

Acular (ketorolac tromethamine ophthalmic solution 0.5%) works by inhibiting prostaglandins in the aqueous humor. Allergan began marketing Acular in 1992 to treat seasonal conjunctival allergies, although the drug did find off-label uses for cystoid macular edemas and post-surgical inflammation.

Acular_334 Drug Information

The Acular_334 drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top